Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.


Journal

Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 12 2 2019
pubmed: 12 2 2019
medline: 2 4 2020
Statut: ppublish

Résumé

Patients with very long chain acyl-CoA dehydrogenase deficiency (VLCADD), a long chain fatty acid oxidation disorder, are traditionally treated with a long chain triglyceride (LCT) restricted and medium chain triglyceride (MCT) supplemented diet. Introduction of VLCADD in newborn screening (NBS) programs has led to the identification of asymptomatic newborns with VLCADD, who may have a more attenuated phenotype and may not need dietary adjustments. To define dietary strategies for individuals with VLCADD based on the predicted phenotype. We evaluated long-term dietary histories of a cohort of individuals diagnosed with VLCADD identified before the introduction of VLCADD in NBS and their beta-oxidation (LC-FAO) flux score (rate of oleate oxidation) in cultured skin fibroblasts in relation to the clinical outcome. Based on these results a dietary strategy is proposed. Sixteen individuals with VLCADD were included. One had an LC-FAO flux score >90%, was not on a restricted diet and is asymptomatic to date. Four patients had an LC-FAO flux score <10%, and significant VLCADD related symptoms despite the use of strict diets including LCT restriction, MCT supplementation and nocturnal gastric drip feeding. Patients with an LC-FAO flux score between 10 and 90% (n = 11) showed a more heterogeneous phenotype. This study shows that a strict diet cannot prevent poor clinical outcome in severely affected patients and that the LC-FAO flux is a good predictor of clinical outcome in individuals with VLCADD identified before its introduction in NBS. Hereby, we propose an individualized dietary strategy based on the LC-FAO flux score.

Sections du résumé

BACKGROUND
Patients with very long chain acyl-CoA dehydrogenase deficiency (VLCADD), a long chain fatty acid oxidation disorder, are traditionally treated with a long chain triglyceride (LCT) restricted and medium chain triglyceride (MCT) supplemented diet. Introduction of VLCADD in newborn screening (NBS) programs has led to the identification of asymptomatic newborns with VLCADD, who may have a more attenuated phenotype and may not need dietary adjustments.
OBJECTIVE
To define dietary strategies for individuals with VLCADD based on the predicted phenotype.
METHOD
We evaluated long-term dietary histories of a cohort of individuals diagnosed with VLCADD identified before the introduction of VLCADD in NBS and their beta-oxidation (LC-FAO) flux score (rate of oleate oxidation) in cultured skin fibroblasts in relation to the clinical outcome. Based on these results a dietary strategy is proposed.
RESULTS
Sixteen individuals with VLCADD were included. One had an LC-FAO flux score >90%, was not on a restricted diet and is asymptomatic to date. Four patients had an LC-FAO flux score <10%, and significant VLCADD related symptoms despite the use of strict diets including LCT restriction, MCT supplementation and nocturnal gastric drip feeding. Patients with an LC-FAO flux score between 10 and 90% (n = 11) showed a more heterogeneous phenotype.
CONCLUSIONS
This study shows that a strict diet cannot prevent poor clinical outcome in severely affected patients and that the LC-FAO flux is a good predictor of clinical outcome in individuals with VLCADD identified before its introduction in NBS. Hereby, we propose an individualized dietary strategy based on the LC-FAO flux score.

Identifiants

pubmed: 30740737
doi: 10.1002/jimd.12037
doi:

Substances chimiques

Fatty Acids 0
Triglycerides 0
Acyl-CoA Dehydrogenase EC 1.3.8.7
Acyl-CoA Dehydrogenase, Long-Chain EC 1.3.8.8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-168

Informations de copyright

© 2018 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Auteurs

Jeannette C Bleeker (JC)

Department of Metabolic Diseases, Dutch Fatty Acid Oxidation Expertise Center, Wilhelmina Children's Hospital (UMCU), University Medical Center Utrecht, Internal Mail KE 04.306.0, PO Box 85090 3508 AB, Utrecht, Netherlands.
Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, Netherlands.
Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Irene L Kok (IL)

Department of Metabolic Diseases, Dutch Fatty Acid Oxidation Expertise Center, Wilhelmina Children's Hospital (UMCU), University Medical Center Utrecht, Internal Mail KE 04.306.0, PO Box 85090 3508 AB, Utrecht, Netherlands.
Department of Internal Medicine and Dermatology, Dietetics, University Medical Center Utrecht, Utrecht, Netherlands.

Sacha Ferdinandusse (S)

Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, Netherlands.

Maaike de Vries (M)

Department of Pediatrics, Radboud University Medical Center, Nijmegen, Netherlands.

Terry G J Derks (TGJ)

Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands.

Margot F Mulder (MF)

Department of Pediatrics, VU University Medical Center Amsterdam, Amsterdam, Netherlands.

Monique Williams (M)

Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, Netherlands.

Estela Rubio Gozalbo (ER)

Department of Pediatrics and Laboratory Genetic Metabolic Diseases, Maastricht University Medical Center, Maastricht, Netherlands.

Annet M Bosch (AM)

Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Dorine T van den Hurk (DT)

Department of Internal Medicine and Dermatology, Dietetics, University Medical Center Utrecht, Utrecht, Netherlands.

Monique G M de Sain-van der Velden (MGM)

Department of Medical Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.

Hans R Waterham (HR)

Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, Netherlands.

Frits A Wijburg (FA)

Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Gepke Visser (G)

Department of Metabolic Diseases, Dutch Fatty Acid Oxidation Expertise Center, Wilhelmina Children's Hospital (UMCU), University Medical Center Utrecht, Internal Mail KE 04.306.0, PO Box 85090 3508 AB, Utrecht, Netherlands.
Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH